MEDI-0680

N/A

Report date: 2025/03/17 20:00:36

Base Information

Drug NameMEDI-0680
Drug Alias NameAMP-514MEDI-0680
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsKidney NeoplasmsCarcinoma, Renal CellLymphoma, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune Llc
Active IndicationsN/A
Inactive IndicationsKidney NeoplasmsCarcinoma, Renal CellLymphoma, B-Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A